Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177-labelled bombesin analogue

Next Previous
Drug Profile

Lutetium-177-labelled bombesin analogue

Alternative Names: 177Lu-AMBA

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bracco
  • Developer Bracco; Marillion Pharmaceuticals
  • Class Lanthanoid series elements; Peptide hormones
  • Mechanism of Action Bombesin receptor agonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer in Europe (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (IV)
  • 12 Nov 2008 Lutetium-177-labelled bombesin analogue licensed to Marillion Pharmaceuticals worldwide for the treatment of hormone-resistant prostate and metastatic breast cancers

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top